

Curriculum Vitae

Tae Min Kim, M.D., PhD

Personal Information

Office Address:

Department of Internal Medicine

Seoul National University Hospital

101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea

E-mail: gabriel9@snu.ac.kr

Education

- PhD Mar 2008- Feb 2012 Molecular Oncology, Department of Medicine, Seoul National University, Seoul, Korea
- M.Sc. Mar 2003 - Feb 2005 Molecular Oncology, Department of Medicine, Graduate School, Seoul National University, Seoul, Korea
- M.D. Mar 1994 - Feb 2000 Seoul National University College of Medicine, Seoul, Korea

Profession

- Sep 2013 - Recent Associate Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Sep 2009 - Aug 2013 Assistant Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Mar 2009 - Aug 2009 Clinical instructor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

Board Certificate

National Board of Medical Practitioner (2000): No. 69707

Korean Board of Internal Medicine (2005): No. 9522

Research Interests

Lung cancer, Lymphoma

Clinical Interests

Lung cancer, Lymphoma, Rare Cancer

Clinical Trial Experience

87 clinical trials as a principal investigator (including 22 phase 1 trials, as of Jul 2017)

291 clinical trials as a sub-investigator (including 90 phase 1 trials, as of Jul 2017)

Recent GCP training: 16 August, 2016

Publications as main author

Kim HJ, Ock CY, Kim TM, Lee SH, Lee JY, Jung SH, Cho YS, Kim M, Keam B, Kim DW, Kim IH, Heo DS. Comparison of Native Escherichia Coli L-Asparaginase Versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP), in Extranodal NK/T Cell Lymphoma, Nasal Type (NTCL). *Cancer Res Treat* 2017 Jul 3 [Epub ahead of print] (Corresponding author)

Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, Kim YT, Kim JS, Kim SH, Lee JS, Lee SH, Park K, Ku JL, Jeon YK, Chung DH, Park PJ, Kim J, Kim TM, Ju YS. Clonal History and Genetic Predictors of Transformation into Small Cell Carcinomas from Lung Adenocarcinomas. *J Clin Oncol* 2017 May 12 [Epub ahead of print] (Corresponding author)

Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ, Ahn YO, Keam B, Park HH, Kim DW, Kim CW, Heo DS. Novel JAK3-Activating Mutations in Extranodal NK/T-cell Lymphoma, Nasal Type. *Am J Pathol* 2017; 187:980-6. (Corresponding author)

Lee JK, Louzada S, An Y, Kim SY, Kim S, Youk J, Park S, Koo SH, Keam B, Jeon YK, Ku JL, Yang F, Kim TM, Ju YS. Complex Chromosomal Rearrangements by Single Catastrophic Pathogenesis in NUT Midline Carcinoma. *Ann Oncol* 2017; 28: 890-97 (Corresponding author)

Paik JH, Choe YJ, Kim H, Lee JO, Kang HJ, Shin HY, Lee DS, Heo DS, Kim CW, Cho KH, Kim TM, Jeon YK. Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. *Leuk Lymphoma* 2017; 58:53-63. (Corresponding author)

Yang Y, Lim O, Kim TM, Ahn YO, Choi HN, Chung H, Min B, Her JH, Cho SY, Keam B, Lee SH, Kim DW, Hwang YK, Heo DS. Phase I study of random, healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. *Cancer Immunol Res* 2016; 4:215-24. (Corresponding author)

Kim TM, Song A, Kim DW, Kim S, Ahn YO, Keam B, Jeon YK, Lee SH, Chung DH, Heo DS. Mechanisms of Acquired Resistance to AZD9291, a Mutation-Selective, Irreversible EGFR Inhibitor. *J Thorac Oncol* 2015;10:1736-44.

Lee SJ, Kim TM, Kim YJ, Jang KT, Lee HJ, Lee SN, Ahn MS, Hwang IG, Lee S, Lee MH, Lee J. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). *Oncologist* 2015;20:1312-9 (co-1st author).

Keam B, Lee SJ, Kim TM, Paeng JC, Lee SH, Kim DW, Jeon YK, Chung DH, Kang KW, Chung JK, Heo DS.

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. *J Thorac Oncol.* 2015;10:1189-94 (Corresponding author).

Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, Heo DS. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (NSCLC). *Clin Cancer Res.* 2015;21:2379-87 (Co-1st author).

Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). *Ann Hematol.* 2015;94:437-44 (Corresponding author).

Kim TM, Kim DW, Kang YK, Chung J, Song HS, Kim HJ, Kim BS, Lee JS, Kim H, Yang SH, Yuh YJ, Bae SH, Hyun MS, Jeon YK, Kim CW, Heo DS. A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group. *Oncologist.* 2014;19:1129-30.

An YJ, Cho HR, Kim TM, Keam B, Kim JW, Wen H, Park CK, Lee SH, Im SA, Kim JE, Choi SH, Park S. An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients. *Int J Cancer.* 2015;136:162-71 (Co-1st author).

Kim TM, Kim S, Ahn YO, Lee SH, Kim DW, Heo DS. Anti-cancer activity of gemcitabine against natural killer (NK) cell leukemia-lymphoma. *Leuk Lymphoma.* 2014;55:940-3.

Lee E, Kim TM, Lim Y, Jeon YK, Go H, Kim CW, Heo DS. Histologic transformation of Epstein-Barr Virus-positive diffuse large B-cell lymphoma of the elderly. *J Clin Oncol.* 2013;31:e332-4 (Corresponding author).

Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS. Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. *J Thorac Oncol.* 2013;8:415-22 (Co-1st author).

Lee HJ, Kim TM. Reply to commentary on "a case of erdheim-chester disease with asymptomatic renal involvement". *Cancer Res Treat.* 2013;44:280 (Corresponding author).

Park JH, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, Chung DH, Kim YT, Kim YW, Heo DS. Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. *Clin Lung Cancer* 2013;14:383-9 (Corresponding author).

Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M. Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer. *J Mol Diagn*. 2013;15:51-61 (Co-1st author).

Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, Kim DW, Lee DS, Kim CW, Chung JK, Kim IH, Heo DS. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B-cell lymphoma. *Cancer* 2013;119:1195-202.

Lee HJ, Lee KY, Shin DY, Lee YG, Choi SY, Moon KC, Han IK, Kim TM. A case of erdheim-chester disease with asymptomatic renal involvement. *Cancer Res Treat*. 2012;44:146-50. (Corresponding author)

Lee JK, Kim TM, Koh Y, Lee SH, Kim DW, Jeon YK, Chung DH, Yang SC, Kim YT, Kim YW, Heo DS, Bang YJ. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. *Lung Cancer*. 2012;77:460-3. (Corresponding author)

Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YH, Heo DS, Bang YJ. Anaplastic Lymphoma Kinase (ALK) Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. *J Thorac Oncol* 2011; 6:1474-80. (Corresponding author)

Kim TM, Kim KH, Lee MJ, Jeon YK, Lee SH, Kim DW, Kim CW, Kim IH, Khwang SI, Heo DS. First-line therapy with doxycycline in ocular adnexal MALT lymphoma: a retrospective analysis of clinical predictors. *Cancer Sci* 2010;101:1199-203.

Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: New staging system and treatment strategies. *Cancer Sci* 2009;100:2242-8.

Kim TM, Kim JS, Han SW, Hong YS, Kim I, Ha J, Kim SJ, Chung JW, Park JH, Lee D, Park S, Kim BK, Kim NK, Yoon SS. Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. *Thromb Res*. 2009;123:436-43.

Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, Kim HJ, Kim SY, Kim CS, Kim S, Kim JS, Sohn SK, Song HH, Lee JL, Kang YK, Yim CY, Lee WS, Yuh YJ, Kim CW, Heo DS; Lymphoma Subcommittee of the Korean Cancer Study Group. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. *Ann Oncol*. 2008;19:1477-84.

Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH, Kim NK. Local tumor invasiveness is more predictive of survival than international prognostic index in stage I_E/II_E extranodal NK/T-cell lymphoma, nasal type. *Blood*. 2005;106:3785-90.

Community

2003 – Recent, Member of Korean Cancer Study Group

2006 – Recent, Member of Korean Cancer Association

2008 – Recent, Member of Korean Association for Clinical Oncology

2011 – Recent, Member of IASLC

2011 – Recent, Member of ASCO

2016 – Recent, Member of AACR